An Open Label Trial to Assess the Effects of Food on the Pharmacokinetic Parameters of Obeticholic Acid (OCA)

Intercept Pharmaceuticals1 site in 1 country32 target enrollmentAugust 2013

ConditionsHealthy

InterventionsOCA 10 mg OCA 25 mg

DrugsOCA 10 mg OCA 25 mg

Overview

Phase: Phase 1
Intervention: OCA 10 mg
Conditions: Healthy
Sponsor: Intercept Pharmaceuticals
Enrollment: 32
Locations: 1
Primary Endpoint: Maximum concentration (Cmax) - fed and fasted
Status: Completed
Last Updated: 11 years ago

Overview Investigators Eligibility Criteria Arms & Interventions Outcomes Sites Similar Trials

Overview

Brief Summary

This is an open label, randomized, balanced, single center, single dose, trial to assess the pharmacokinetic (PK) profile of OCA, glyco-OCA and tauro-OCA on an empty stomach (fasted condition) and following a high fat, high calorie meal (fed condition) in a 2-period, 2-sequence, crossover manner.

Registry

clinicaltrials.gov

Start Date

August 2013

End Date

November 2013

Last Updated

11 years ago

Study Type

Interventional

Study Design

Crossover

Sex

All

Investigators

Sponsor

Intercept Pharmaceuticals

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Subjects are required to meet the following criteria in order to be included in the trial.
•Male or female subjects from 18 to 55 years
•Contraception: Female subjects must be postmenopausal, surgically sterile, or if premenopausal, be prepared to use more than 1 effective (≤ 1% failure rate) method of contraception during the trial and until at least 30 days after the last dose of OCA. Effective methods of contraception are considered to be:
•Double barrier method, ie, (a) condom (male or female) with spermicide or (b) diaphragm with spermicide
•Intrauterine device (IUD)
•Good general health as determined by medical history, and by results of physical examination, vital signs, electrocardiogram (ECG), and clinical laboratory tests obtained within 14 days prior to Day 0
•Body mass index (BMI) of 18 to 28; BMI is determined by the following equation: BMI = weight/height2 (kg/m2).
•Willing to abstain from alcohol, caffeine, and xanthine-containing food and beverages for 72 hours prior to each period check in and during participation of the inpatient periods of the trial
•Willing and able to give written informed consent

Exclusion Criteria

•Subjects meeting the following criteria will be excluded from the trial.
•Prior participation in a clinical trial of OCA (INT-747; 6-ECDCA)
•History or presence of any disease or condition known to interfere with the absorption, distribution, metabolism, or excretion of drugs including bile salt metabolism in the large intestine, eg, inflammatory bowel disease
•History of gastrointestinal surgeries or gall bladder removal (cholecystectomy)
•History or presence of a clinically significant cardiovascular, hepatic, diabetic, gastrointestinal, metabolic, neurologic, pulmonary, endocrine, psychiatric, or neoplastic disorder(s)
•History of known or suspected clinically significant hypersensitivity to any drug, aside from penicillin
•Ingestion of a prescription medication within 14 days prior to Day 0 or ingestion of an over the counter medication within 7 days prior to Day 0
•Participation in radiologic examinations involving parenteral administration of iodinated contrast materials within 2 weeks prior to screening, or subsequently, through the end of trial participation
•History or presence of alcohol abuse (defined as consumption of more than 210 mL of alcohol per week; or the equivalent of fourteen 4 ounces (oz) glasses of wine, or fourteen 12 oz cans/bottles of beer or wine coolers per week)
•History or presence of substance abuse within the past 2 years or positive drug screen tests